The Current Ratio as of November 2024 (TTM) for Mereo BioPharma Group plc (MREO) is 6.10

According to Mereo BioPharma Group plc’s latest financial reports and current stock price. The company's current Current Ratio is 6.10. This represents a change of 2.75% compared to the average of 5.94 of the last 4 quarters.

Mereo BioPharma Group plc (MREO) Historical Current Ratio (quarterly & annually)

How has MREO Current Ratio performed in the past?

The mean historical Current Ratio of Mereo BioPharma Group plc over the last ten years is 8.68. The current 6.10 Current Ratio has changed 6.93% with respect to the historical average. Over the past ten years (40 quarters), MREO's Current Ratio was at its highest in in the December 2015 quarter at 28.85. The Current Ratio was at its lowest in in the March 2016 quarter at 0.

Mereo BioPharma Group plc (MREO) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Mereo BioPharma Group plc Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Mereo BioPharma Group plc (MREO) Average Current Ratio

How has MREO Current Ratio performed in the past?

The current Current Ratio of Mereo BioPharma Group plc (MREO) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Mereo BioPharma Group plc (MREO) Current Ratio vs. Peers

How is MREO’s Current Ratio compared to its peers?

Mereo BioPharma Group plc’s Current Ratio is less than Terns Pharmaceuticals, Inc. (32.99), greater than PDS Biotechnology Corporation (2.84), less than Inozyme Pharma, Inc. (7.68), greater than HOOKIPA Pharma Inc. (3.26), less than Day One Biopharmaceuticals, Inc. (14.62), greater than X4 Pharmaceuticals, Inc. (4.89), less than Acumen Pharmaceuticals, Inc. (10.43), greater than Amylyx Pharmaceuticals, Inc. (4.55), greater than eFFECTOR Therapeutics, Inc. (1.03), less than Elevation Oncology, Inc. (17.77), greater than Hepion Pharmaceuticals, Inc. (1.30),

Build a custom stock screener for Mereo BioPharma Group plc (MREO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mereo BioPharma Group plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mereo BioPharma Group plc (MREO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mereo BioPharma Group plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.